A new Moffitt Cancer Center study suggests a widely used genomic test can more accurately identify which men with early prostate cancer are at high risk for their disease to come back quickly after ...
The study's testing accurately identified prostate cancer 91% of the time and accurately ruled out men without prostate cancer 84% of the time. A urine-based biomarker panel may be a promising, ...
Profiling BCRAness phenotype in public prostate cancer datasets without homologous repair gene mutations. Cardiometabolic health’s influence on outcomes in men with localized high-risk prostate cancer ...
To check for possible prostate cancer, physicians most often use prostate-specific antigen (PSA) tests and digital rectal exams (DREs). For a firm diagnosis, they use core needle biopsies. This page ...
Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. This voice experience is generated by AI. Learn more. This voice ...
Prostate cancer is the most commonly diagnosed cancer among men in the United Kingdom. Because of this, many men look for ...
More than 15 abstracts showcase how the Veracyte Diagnostics Platform is advancing urologic cancer care with decisions guided by Decipher Prostate and Bladder tests Veracyte, Inc. (Nasdaq: VCYT), a ...
Add Yahoo as a preferred source to see more of our stories on Google. The scan works by using a molecule that binds to prostate cancer cells, causing them to appear as bright spots on imaging A scan ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results